BioCentury
ARTICLE | Clinical News

APL-130277: Phase II started

July 28, 2014 7:00 AM UTC

Cynapsus began the open-label, U.S. Phase II CTH-105 trial to evaluate titrated doses of APL-130227 in 16 apomorphine-naive PD patients who experience >=1 daily “off” episode with a total duration of “off” in any 24-hour period of >=2 hours. Next quarter, the company plans to begin the double-blind, placebo-controlled CTH-300a clinical trial based on data from CTH-105. The primary endpoint of CTH-300a will be the change in the Unified Parkinson’s Disease Rating Scale (UPDRS) Part III score. ...